Changes in ALT concentrations from baseline were similar in stable patients compared to those with progressed disease when measured by the fibrosis and NASH assessment, though with the fibrosis score participants were more variable (Figure 2). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.